Distribution and Expression of Programmed Death Ligand -1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India
Objective: Non-small cell lung carcinomas often present at an advanced stage with a grim prognosis. Immune checkpoint (ICP) inhibitors have drastically changed the scenario, and the response to ICP inhibitors is determined by analyzing the expression of PD-L1 by immunohistochemistry. PD-L1 immunohis...
Saved in:
Main Author: | Sheba S K JACOB (Author) |
---|---|
Format: | Book |
Published: |
Federation of Turkish Pathology Societies,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
by: Opal L. Reddy, et al.
Published: (2017) -
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors
by: Kemal KÖSEMEHMETOĞLU, et al.
Published: (2017) -
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018) -
Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
by: Bharat Jasani, et al.
Published: (2020) -
PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
by: Min Luo, et al.
Published: (2021)